Randomized Study to Evaluate the Use of High-Dose Therapy as Part of Primary Treatment for “Aggressive” Lymphoma

Kaiser, Ulrich; Uebelacker, Irmgard; Abel, Ulrich; Birkmann, Josef; Trümper, Lorenz; Schmalenberg, Harald; Karakas, Tunca; Metzner, Bernd; Hossfeld, Dieter K.; Bischoff, Helge; Franke, Astrid; Reiser, Marcel; Müller, Peter E.; Mantovani, Luisa; Grundeis, Marc; Rothmann, Frank; Seydewitz, Cay-Uwe von; Mesters, Rolf M.; Steinhauer, E. U.; Krahl, Dorothea; Schumacher, K.; Kneba, Michael; Baudis, Michael; Schmitz, Norbert; Pfab, R; Köppler, H.; Parwaresch, Reza; Pfreundschuh, Michael; Havemann, K.

doi:10.1200/jco.2002.07.075

Cited by 123 publications

(63 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…9 Although this study is not a concurrent comparison of treatment options and any conclusions between nonrandomized groups may be subject to differences in observed and unobserved prognostic factors, it is unlikely that the differences in outcome seen in control and auto-SCT groups are caused by factors other than treatment. While both negative and positive impact of upfront HDT and auto-SCT on survival have been reported, [20][21][22][23][24] our findings are in line with positive studies, which suggested that especially young high-risk patients benefit from upfront HDT. 21,24 The finding showing that the benefit of HDT and auto-SCT is only seen in the non-GC subgroup is also important as it highlights the fact that two phenotypes are biologically and clinically distinct.…”

Section: Discussionsupporting

confidence: 81%

Impact of germinal center and non-germinal center phenotypes on overall and failure-free survival after high-dose chemotherapy and auto-SCT in primary diffuse large B-cell lymphoma

Nyman

Jantunen

Juvonen

et al. 2008

Bone Marrow Transplant

View full text Add to dashboard Cite

Non-germinal center (non-GC) phenotype is an adverse prognostic factor in chemotherapy (CT)-treated diffuse large B-cell lymphoma (DLBCL) patients. To determine how high-dose therapy (HDT) supported with auto-SCT as first line therapy influences GC-associated outcome in young high-risk DLBCL patients GC and non-GC phenotypes were determined immunohistochemically from 63 patients. Of these, 29 primary high-risk DLBCL patients were treated with auto-SCT, whereas 34 CT-treated patients served as a control group. Consistent with previous studies, non-GC phenotype was associated with adverse outcome in CT-treated high-risk patients. In contrast, immunohistochemical classification by cell of origin did not associate with survival after auto-SCT. When the impact of treatment on the predictive value of cell of origin was analyzed, the non-GC patients, who received HDT, had a better failure-free survival (FFS) and overall survival (OS) than the patients treated with CT alone. In multivariate analyses, both age-adjusted International Prognostic Index (aaIPI) and treatment were independent prognostic factors for FFS and OS. For the patients with GC phenotype, the influence of auto-SCT on survival was not significant. The data imply that auto-SCT can overcome the adverse prognostic impact of the non-GC phenotype in patients with high-risk DLBCL and warrant additional prospective studies.

show abstract

Section: Discussionsupporting

confidence: 81%

Impact of germinal center and non-germinal center phenotypes on overall and failure-free survival after high-dose chemotherapy and auto-SCT in primary diffuse large B-cell lymphoma

Nyman

Jantunen

Juvonen

et al. 2008

Bone Marrow Transplant

View full text Add to dashboard Cite

show abstract

“…14 Some studies, in particular, have shown little or no benefit from up-front dose intensification. [15][16][17][18] Risk-adapted therapy may be performed after patient stratification according to International Prognostic Index (IPI) score 19 or, as demonstrated recently, by applying a standardized and widely acknowledged molecular or immunohistochemical profiling, particularly in a high-grade lymphoma setting. [20][21][22][23] Although the IPI score represents the most reliable prognostic index in aggressive lymphomas, patients belonging to the same IPI prognostic group may show significantly different outcomes, primarily because diffuse large B-cell lymphoma (DLBCL) tends to behave heterogeneously.…”

mentioning

confidence: 99%

Midtreatment ¹⁸F‐fluorodeoxyglucose positron‐emission tomography in aggressive non‐Hodgkin lymphoma

Zinzani

Gandolfi

Broccoli

et al. 2010

Cancer

View full text Add to dashboard Cite

Herein, we report on direct preparation of macroporous polyimide (PI) films with pores distributing on one side, the method of which relies on sedimentation of ceramic spheres in polyamic acid (PAA) solutions in a gravitational field and imidization of PAA/ceramic spheres mixtures to obtain PI/ceramic spheres hybrid films followed by curing in dilute hydrofluoric (HF) acid. In this strategy, the curing of the hybrid films in HF acid leads to the formation of pores. The introduction of pores makes the room‐temperature dielectric constants of the macroporous films lower than that of pure PI film. Moreover, the macroporous PI films have improved Young's moduli and higher thermal stability in nitrogen atmosphere. © 2007 Wiley Periodicals, Inc. J Appl Polym Sci 104: 261–266, 2007

show abstract

“…Clinical treatment protocols in high-income countries are based on the FAB LMB study or the Berlin-Frankfurt-Muenster protocols and achieve outstanding overall survival rates in children (3). Nevertheless, there are cases of poor clinical outcome caused by the toxicity of the intensive chemotherapy, tumor lysis syndrome, or metastatic spread of lymphoma cells to the central nervous system (4)(5)(6)(7). Especially elderly and HIV-positive patients show a poorer overall survival rate because of treatment-related mortality (3,8,9).…”

Section: Introductionmentioning

confidence: 99%

The NADPH Oxidase Inhibitor Imipramine-Blue in the Treatment of Burkitt Lymphoma

Klingenberg¹,

Becker²,

Eberth³

et al. 2014

Molecular Cancer Therapeutics

View full text Add to dashboard Cite

Burkitt lymphoma is a rare malignancy arising from B cells. Current chemotherapeutic regimens achieve excellent overall survival rates in children, but less impressive rates in adults. There are cases with poor outcome caused by toxic effects of the therapy, tumor lysis syndrome, or metastatic spread of lymphomas to the central nervous system. Modulators of reactive oxygen species are currently discussed as potential drugs for the treatment of cancer. The NADPH oxidase 4 inhibitor imipramine-blue might satisfy the aforementioned requirements, and was studied here. We used MTT assay, crystal violet assay, and thymidine 3H-incorporation assay to analyze the effects of imipramine-blue on Burkitt lymphoma (BL2, BL2B95, BL30B95, BL41B95), neuroblastoma (KELLY, SH-SY5Y, SMS-KAN), cervix carcinoma (HeLa), breast cancer (MDA-MB231), angiosarcoma (AS-M), human embryonic kidney (HEK293WT), and nonmalignant (FLP1) cell lines. The effects of imipramine-blue on BL2B95 cells in vivo were investigated in xenografts on the chick chorioallantoic membrane (CAM). We report that imipramine-blue is a potent growth inhibitor for several cancer cell lines in vitro with IC 50 values comparable to those of doxorubicin (0.16-7.7 mmol/L). Tumor size of BL2B95 cells inoculated in the CAM was reduced significantly (P < 0.05) after treatment with 10 mmol/L imipramine-blue. Lymphogenic dissemination of BL2B95 and the formation of blood and lymphatic vessels in experimental tumors were not affected. We show that imipramine-blue can be used to decrease the viability of cancer cell lines in vitro and in vivo. Imipramine-blue reduces the size of experimental Burkitt lymphoma significantly but does not affect the dissemination of BL2B95 cells, angiogenesis, and lymphangiogenesis.

show abstract

Randomized Study to Evaluate the Use of High-Dose Therapy as Part of Primary Treatment for “Aggressive” Lymphoma

Abstract: Results of the randomized trial comparing CHOP-like chemotherapy with early HDT do not support the use of HDT with carmustine, etoposide, cytarabine, and melphalan following shortened standard chemotherapy.

Cited by 123 publications

References 17 publications

Impact of germinal center and non-germinal center phenotypes on overall and failure-free survival after high-dose chemotherapy and auto-SCT in primary diffuse large B-cell lymphoma

Impact of germinal center and non-germinal center phenotypes on overall and failure-free survival after high-dose chemotherapy and auto-SCT in primary diffuse large B-cell lymphoma

Midtreatment ¹⁸F‐fluorodeoxyglucose positron‐emission tomography in aggressive non‐Hodgkin lymphoma

The NADPH Oxidase Inhibitor Imipramine-Blue in the Treatment of Burkitt Lymphoma

Contact Info

Product

Resources

About

Randomized Study to Evaluate the Use of High-Dose Therapy as Part of Primary Treatment for “Aggressive” Lymphoma

Abstract: Results of the randomized trial comparing CHOP-like chemotherapy with early HDT do not support the use of HDT with carmustine, etoposide, cytarabine, and melphalan following shortened standard chemotherapy.

Cited by 123 publications

References 17 publications

Impact of germinal center and non-germinal center phenotypes on overall and failure-free survival after high-dose chemotherapy and auto-SCT in primary diffuse large B-cell lymphoma

Impact of germinal center and non-germinal center phenotypes on overall and failure-free survival after high-dose chemotherapy and auto-SCT in primary diffuse large B-cell lymphoma

Midtreatment 18F‐fluorodeoxyglucose positron‐emission tomography in aggressive non‐Hodgkin lymphoma

The NADPH Oxidase Inhibitor Imipramine-Blue in the Treatment of Burkitt Lymphoma

Contact Info

Product

Resources

About

Midtreatment ¹⁸F‐fluorodeoxyglucose positron‐emission tomography in aggressive non‐Hodgkin lymphoma